News & Updates
Showing Multidisciplinary articles
Showing

Darolutamide + ADT, without docetaxel, shows efficacy benefits in mHSPC
Darolutamide plus androgen-deprivation therapy (ADT), without docetaxel, improves radiological progression-free survival (rPFS) and secondary efficacy outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results of the global phase III ARANOTE trial presented at ESMO 2024.

Aspirin may improve survival in PIK3CA-mutated colon cancer
Adjuvant treatment with aspirin appears to provide some protection in patients with resected, PIK3CA-mutant stage II and III colon cancer, demonstrating a clinically significant improvement (43 percent) in disease-free survival (DFS), suggests a study presented at ESMO Congress 2024.

Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag
In the treatment of patients with pulmonary arterial hypertension, adding selexipag as a third medication sooner rather than later is crucial to help prevent hospitalization and disease progression, as suggested in an emulated target trial.





